Antibody-drug conjugates (ADCs) combine a monoclonal antibody with a chemotherapy drug through a stable chemical linker. This lets them deliver potent cytotoxic agents directly to tumor cells while limiting damage to healthy tissue, which sets them apart from traditional chemotherapy. ADCs are moving from a niche oncology segment to a core pillar of precision cancer treatment.

Market Size and Growth Projections

The global antibody drug conjugates market was valued at USD 14.5 billion in 2025. It is projected to grow from USD 16.7 billion in 2026 to USD 32.1 billion by 2033, a CAGR of 11.5% over 2026-2033. That is more than a doubling of the 2025 base.

Key segment and regional highlights:

• Region: North America led with a 39.80% revenue share in 2025, and Asia Pacific is the fastest-growing region, with a projected CAGR of 11.77%.
• Application: Breast cancer held the largest share at 40.8% in 2025. Urothelial carcinoma is projected to grow fastest.
• Payload: Auristatins (MMAE, MMAF) led with 35.9%. Topoisomerase I inhibitors (SN-38, DXd) are expected to grow fastest.
• Technology: Cleavable linkers held 67.7%, while non-cleavable linkers are projected to see the highest growth.
• Distribution: Hospital pharmacies held 52.8%, and specialty pharmacies are expected to grow fastest through 2033.

Key Blockbuster Products and Sales

Product performance is best measured by revenue share of the overall market.

Enhertu (trastuzumab deruxtecan), AstraZeneca/Daiichi Sankyo is the clear leader. It held the largest product share, 27.9% of 2025 revenue. Applied to the USD 14.5 billion market, that works out to roughly USD 4.0 billion. Its momentum comes from:

• A June 2024 tumor-agnostic FDA approval for previously treated HER2-positive solid tumors.
• A January 2025 U.S. approval for HR-positive, HER2-low/ultralow breast cancer, which significantly expanded the eligible population.
• Standardized ILD monitoring, which has increased clinician confidence, and reimbursement approvals across the U.S., EU5 and APAC.
• Planned ADC manufacturing expansion in Singapore to strengthen supply resilience.

The other established brands:

• Kadcyla (Roche/Genentech): received adjuvant approval in May 2019, establishing an early market position in breast cancer.
• Trodelvy (Gilead): continues to contribute to demand in metastatic triple-negative breast cancer, including cases with minimal or absent HER2 expression.
• Adcetris (Seagen/Pfizer, Takeda): a CD30-targeted ADC with an MMAE payload, used in blood cancers.
• Polivy (Roche): a CD79b-targeted ADC with an MMAE payload for specific B-cell malignancies.
• Padcev (Astellas/Pfizer): approved in December 2023 with pembrolizumab as a first-line regimen for urothelial carcinoma, following the EV-302/KEYNOTE-A39 trial's superior survival outcomes.
• Datroway (AstraZeneca/Daiichi Sankyo): approved in February 2025 for HR-positive, HER2-negative breast cancer and in June 2025 for previously treated advanced non-small cell lung cancer.
• Others: Tivdak, Elahere, Zynlonta, Mylotarg and Besponsa.

Ready to Navigate the ADC Landscape? Whether you're evaluating partnerships, planning a pipeline strategy, or sizing a new opportunity, the next few years will reward the teams that move early and decide with data. Download the Free Sample Report

Major Industry Drivers

Clinical validation and regulatory approvals. Growing clinical validation across cancer indications has increased oncologists' confidence, and ADCs are increasingly part of treatment guidelines for solid and hematological tumors. Enhertu's expanding label and Datroway's approval encouraged further R&D investment.

Technology advances. Advances in antibody engineering, linker technologies and payload design have improved precision. Innovation extends to payload diversity beyond MMAE and DM4 and to new antigen targets beyond HER2 and CD30.

Rising cancer burden. Growth is tied primarily to increasing cancer prevalence and demand for targeted therapies that offer greater efficacy with reduced systemic toxicity.

New tumor types and earlier treatment lines. The pipeline targets lung, gastrointestinal, genitourinary and gynecologic cancers, and studies are testing ADCs in earlier lines of therapy.

Geographic expansion. Players are entering Asia Pacific, Latin America and the Middle East, with Japan, China and India gaining prominence as trial hubs and commercial targets.

Constraints to watch. High development and manufacturing costs, complex supply chains, off-target toxicity concerns and stringent regulation all weigh on growth. Competition from immune checkpoint inhibitors, CAR-T therapies and small-molecule inhibitors is also a substitution risk.

M&A and Partnership Activity

A steady stream of deals shows how much big pharma wants a stake in ADCs:

• Pfizer–Seagen: Pfizer strengthened its position through the acquisition of Seagen and its established ADC portfolio.
• J&J–Ambrx (January 2024): Johnson & Johnson completed its acquisition of Ambrx Biopharma to strengthen its oncology portfolio, particularly in prostate cancer, using Ambrx's ADC platform.
• Roche–MediLink (January 2024): a licensing and collaboration agreement to advance YL211, a next-generation ADC.
• Celltrion–WuXi XDC (January 2024): an MoU for integrated ADC development and manufacturing services.
• AstraZeneca–EsoBiotec (March 2025): an agreement to acquire the biotech for up to $1 billion to expand its investments in cell therapies for cancer treatment.
• BioNTech–Bristol Myers Squibb (June 2025): a collaboration to co-develop and commercialize BNT327, with BioNTech receiving a $1.5 billion upfront payment and up to $7.6 billion in potential milestones.
• Roche–Innovent (2025): a collaboration on a DLL3-targeting ADC, reflecting the push into difficult-to-treat tumors.

Speak to an Analyst Have a specific question about ADC trends, targets or competitors? Reach out and our team will get back to you within one business day.

The Bottom Line

The market is increasingly consolidating around companies with proven ADC capabilities and commercialization infrastructure. AstraZeneca and Daiichi Sankyo set the benchmark with Enhertu, while Pfizer, Roche, Gilead and Takeda use broad oncology franchises to extend ADCs across tumor types. With a projected path from USD 14.5 billion to USD 32.1 billion by 2033, ADCs look set to remain one of oncology's most important innovation areas.

Explore our dedicated business services:

Prism AI: Market Intelligence with Cited Research- Ask questions in plain language and get insights drawn from Grand View Research's entire research library, with sources cited. Create your free account today.

U.S. Healthcare Facility Mapping & Intelligence Platform: Get facility-level intelligence to guide smarter decisions. Sign up Today